27.03.2020
Growing importance of nuclear medicine for the treatment of cancer
Debiopharm expands its radiopharmaceutical footprint with an exclusive in-licensing agreement of 3B Pharmaceutical’s targeted CAIX radiotherapy:
Debiopharm, a Swiss-based biopharmaceutical company announced having entered into a worldwide, exclusive license & research agreement with 3B Pharmaceuticals (3BP), a German biotechnology firm, to further the…